High prevalence of hepatitis C (HCV) in the emergency department (ED) of a London hospital: should we be screening for HCV in ED attendees?

Author:

ORKIN C.,LEACH E.,FLANAGAN S.,WALLIS E.,RUF M.,FOSTER G. R.,TONG C. Y. W.

Abstract

SUMMARYAn unlinked anonymous study was conducted to estimate the prevalence of hepatitis C virus (HCV) infection in emergency department (ED) attendees at a London Hospital. Nine hundred and ninety-seven samples collected over a 12-day period were tested for HCV antibody (Ab) and reactive samples were further tested for HCV RNA. The HCV seroprevalence was 2·6% (26/997) with 1·2% (12/997) HCV RNA positive. A peak HCV RNA-positive prevalence of 4·8% (3/63) was found in males aged 35–44 years, this was compared to 0% (0/136) in males aged <35 years (P = 0·0614) and 1·4% (4/278) in males aged ⩾45 years (P = 0·2415). Assuming the cost for HCV Ab is £6 and HCV RNA is £40 per test, screening ED attendees aged 25–54 years would cost £360 per viraemic infection and identify 82% of those who were HCV RNA positive, yielding the most favourable cost/benefit ratio. HCV screening of ED attendees aged 25–54 years in this population could be an effective way of identifying patients and limit onward transmission.

Publisher

Cambridge University Press (CUP)

Subject

Infectious Diseases,Epidemiology

Reference12 articles.

1. Sofosbuvir and ledipasvir fixed-dose combination with and without ribavirin in treatment-naive and previously treated patients with genotype 1 hepatitis C virus infection (LONESTAR): an open-label, randomised, phase 2 trial

2. Epidemiology and natural history of HCV infection

3. National Institute of Clinical Excellence. Hepatitis B and C: ways to promote and offer testing to people at increased risk of infection. 2014 (http://www.nice.org.uk/guidance/ph43/resources/hepatitis-b-and-c-ways-to-promote-and-offer-testing-draft-guidance2). Accessed 11 November 2014.

4. Hospital Episode Statistics. Accident and emergency attendances in England. Health and Social Care Information Centre. 2014 (http://www.hscic.gov.uk/catalogue/PUB13464/acci-emer-atte-eng-2012-2013-rep.pdf) Accessed 24 November 2014.

5. The changing therapeutic landscape for hepatitis C

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3